Actelion Ltd (ALIOF) 164.2900 $ALIOF Is ACTELION (ALIOF)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actelion Ltd (ALIOF) 164.2900 $ALIOF

Is ACTELION (ALIOF) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:35AM CDT
ACTELION (ALIOF) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.

Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:32AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.14 per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.76.
AGEN: 6.22 (+0.28), BIIB: 315.00 (+1.06), ICPT: 162.99 (+5.30)

Merrimack (MACK) Q2 Loss Wider than Expected, Sales Top
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 3:02PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 40 cents per share in the second quarter of 2016, wider than the Zacks Consensus Estimate of 34 cents.
MACK: 5.20 (+0.02)

Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 2:52PM CDT
Exelixis, Inc. (EXEL) posted a second-quarter 2016 loss of 16 cents, narrower than both the Zacks Consensus Estimate of 27 cents and the year-ago loss of 22 cents
BIIB: 315.00 (+1.06), EXEL: 10.66 (unch)

Why ACTELION (ALIOF) Could Be an Impressive Growth Stock
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:37AM CDT
ACTELION can captivate investors' attention and produce gains, being well positioned for future earnings growth.

3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 24.16 (-0.02), GILD: 79.84 (+0.18), MRK: 63.35 (-0.28), UTHR: 125.19 (+0.86)

Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved
Globe Newswire - Wed May 04, 5:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 26.87 (-0.73), UTHR: 125.19 (+0.86), AEGR: 1.57 (+0.02)

Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio
Globe Newswire - Thu Apr 21, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Clovis Hits 52-week Low Post Rociletinib Briefing Documents
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 2:45PM CDT
Clovis Oncology's (CLVS) shares touched a 52-week low with the FDA raising concerns related to the lung cancer treatment, rociletinib, in its briefing documents.
EBS: 26.87 (-0.73), CLVS: 16.87 (+0.66), ANIK: 48.79 (-0.15)

Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 3:40PM CDT
Ionis Pharmaceuticals' (IONS) shares plunged 11% after the FDA placed a clinical hold on the phase III CARDIO-TTR study on IONIS-TTRRx.
BIIB: 315.00 (+1.06), GSK: 44.51 (+0.34), IONS: 35.00 (-0.03)

Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.49 (-0.08), SCMP: 11.61 (-0.16), ICPT: 162.99 (+5.30)

Illumina Unveils BaseSpace Suite, Boosts Precision Medicine
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 12:55PM CDT
Illumina, Inc. (ILMN) recently launched its BaseSpace Informatics suite to facilitate precision medicine and genomics research.
ILMN: 166.99 (-1.03), AMAG: 24.44 (+1.35), ANIK: 48.79 (-0.15)

Seres Therapeutics (MCRB) in Focus: Stock Up 5.5% in Session
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:35AM CDT
Seres Therapeutics, Inc. (MCRB) was a big mover last session, as the company saw its shares rise around 6% on the day.
MCRB: 10.57 (+0.04)

Ironwood Slumps, Halts Development of Gastroparesis Drug
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:10AM CDT
Ironwood Pharmaceuticals (IRWD) plans to discontinue the development of IW-9179 for diabetic gastroparesis after unfavorable phase IIa study results; shares fall.
IRWD: 13.36 (+0.02), EBS: 26.87 (-0.73), AMAG: 24.44 (+1.35)

Actelion issues invitation to 2016 Annual General Meeting of Shareholders
Globe Newswire - Wed Apr 06, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Actelion issues invitation to 2016 Annual General Meeting of Shareholders . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

AbbVie Up, Wins CHMP Backing for Humira's Expanded Use
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 10:20AM CDT
AbbVie Inc. (ABBV) announced that the EMA's CHMP has rendered an opinion in favor of expanding Humira's label in the EU.
EBS: 26.87 (-0.73), ABBV: 67.15 (-0.04), AMAG: 24.44 (+1.35)

Abeona Therapeutics (ABEO) Jumps: Stock Rises 6.4%
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:40AM CDT
Abeona Therapeutics Inc. (ABEO) saw its shares rise above 6% in the last trading session.
ABEO: 3.58 (-0.03)

Bristol-Myers Gets CHMP Backing for Opdivo's Expanded Use
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 3:10PM CDT
Bristol-Myers' (BMY) Opdivo gets CHMP backing for label expansion of Opdivo in combination with Yervoy for advanced (unresectable or metastatic) melanoma.
AMAG: 24.44 (+1.35), BMY: 60.83 (+0.20), ANIK: 48.79 (-0.15)

Regeneron, Sanofi Up, Eczema Drug Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 2:40PM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi's atopic dermatitis candidate dupilumab scores in phase III studies; shares up.
AMAG: 24.44 (+1.35), SNY: 40.16 (unch), REGN: 421.54 (+0.19)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 218

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

SRM Entertainment Expands Horizon with Strategic Moves.

Updated Category News Views 238

SRM Entertainment's Strategic Growth Plans SRM Entertainment, Inc. (Nasdaq: SRM) is taking bold steps to enhance its market position and create long-term value for its shareholders. Despite receiving numerous inquiries from investors regarding potential capital raises, the company has confirmed no immediate plans to seek additional funding. This strategic decision aligns...

Continue Reading
SBA Communications Unveils Tax Reporting Details for 2024

Updated Category News Views 149

SBA Communications Corporation Announces 2024 Tax Reporting Insights SBA Communications Corporation (Nasdaq: SBAC) has shared important tax reporting information concerning its distributions for 2024. As stockholders prepare for their tax obligations, the company encourages them to seek advice from their personal tax advisors to ensure they understand their specific tax...

Continue Reading
electroCore Achieves Significant Milestone with New Patents

Updated Category News Views 157

electroCore Enhances Innovation Through New Patents electroCore, Inc. (NASDAQ: ECOR), a leading figure in the bioelectronic medicine and wellness space, has recently made headlines by receiving notifications for five new patents issued by the United States Patent and Trademark Office (USPTO). This expansion of its intellectual property portfolio not only underscores...

Continue Reading
Empowering Grassroots: A Great Idea’s New Microgrant Initiative

Updated Category News Views 252

Introducing the A Great Idealist Microgrant Program A Great Idea (AGI) has recently unveiled its A Great Idealist Microgrants program, designed to provide crucial financial support to grassroots organizers, community advocates, and innovative leaders across the nation. This initiative echoes AGI's commitment to uplift and empower those at the forefront of social change....

Continue Reading
Elevat and HydraForce Team Up for Game-Changing Solutions

Updated Category News Views 249

Dynamic Partnership Set to Transform OEM Offerings What’s brewing in the world of industrial machine intelligence? It’s more than a merger—it’s a strategic collaboration that’s about to shake things up. Elevat, that Seattle-based powerhouse known for its cutting-edge solutions, has joined forces with HydraForce, backed by Bosch, to roll out some impressive...

Continue Reading